Petmed Express ( (PETS) ) has provided an announcement.
On April 9, 2025, PetMed Express, Inc. announced the appointment of Peter Batushansky to its Board of Directors, expanding the board from six to seven members. Mr. Batushansky, who brings over 20 years of experience in retail, pet, healthcare, and private equity, will also serve on the Audit and Corporate Governance and Nominating Committees. His appointment is part of the company’s strategic board refreshment to support its transformation strategy. Concurrently, longtime board member and former Chairman Dr. Gian Fulgoni announced his intention to retire at the 2025 annual shareholders’ meeting, after which the board will revert to six members.
Spark’s Take on PETS Stock
According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.
Petmed Express’s overall stock score reflects a mixed financial and strategic outlook. Strong balance sheet stability is offset by weak profitability and overvaluation concerns. The recent earnings call highlights improvements in profitability and cost management, but declining sales and a challenging competitive environment weigh on the score. Technical indicators suggest bearish trends, further impacting the overall assessment.
To see Spark’s full report on PETS stock, click here.
More about Petmed Express
Founded in 1996, PetMed Express, Inc. is a leader in the consumer pet healthcare sector, operating as a national online retailer with expert pharmacists and licenses across all fifty states. Through its websites PetMeds.com and PetCareRx.com, the company provides top branded pharmaceuticals, generics, compounded prescription medications, and OTC supplements and vitamins, aiming to enhance the wellness and longevity of pets such as dogs, cats, and horses.
YTD Price Performance: -33.62%
Average Trading Volume: 251,546
Technical Sentiment Signal: Strong Buy
Current Market Cap: $68.58M
For a thorough assessment of PETS stock, go to TipRanks’ Stock Analysis page.